-
Citigroup raises Johnson&Johnson's target price from $180 to $185
Citigroup has raised Johnson&Johnson's target price from $180 to $185. -
Johnson&Johnson China CEO Song Weiqun steps down as Chairman of Johnson&Johnson China
Southern Finance and Economics, September 23rd - According to Tianyancha App, Johnson&Johnson (China) Investment Co., Ltd. has undergone a business change recently, with Song Weiqun stepping down as ... -
Johnson&Johnson China completes business changes, with Song Weiqun stepping down as chairman
According to the Tianyancha App, on September 18th, Johnson&Johnson (China) Investment Co., Ltd. underwent a business change, with Song Weiqun stepping down as the legal representative and chairman, ... -
Johnson&Johnson appoints Zhou Mintao as President of Medical Technology China
Johnson&Johnson announced on July 15th that Edward Zhou will serve as the President of its Medical Technology China region from July 25th, 2024, reporting to Vishnu Karla, the Chairman of Johnson&Joh ... -
Qiangsheng subsidiary responds to "shortage of focus in Daduo": the company faces supply pressure and challenges due to a significant increase in market demand
Johnson&Johnson subsidiary responds to "shortage of focus on delivery in many areas": the company is facing supply pressure and challenges due to a significant increase in market demand. Recently, th ... -
Is Johnson&Johnson clearing Kenvue shares and withdrawing from the skincare and beauty industry a win-win situation or a last resort?
Recently, Kenvue (KVUE. US) announced on its official website that Johnson&Johnson (JNJ. US) will sell its remaining 9.5% stake in the company to Goldman Sachs and JPMorgan Chase in a debt to equity ... -
Johnson&Johnson plans to acquire biotech company Proteology for $850 million
On May 16th, Johnson&Johnson announced that they had reached a final agreement with Proteology to acquire biotechnology company Proteology for $850 million in cash. The transaction is expected to be ... -
Kenvue, Global layoffs: Johnson&Johnson plans to clear its holdings, raise prices to sustain sales, and it is difficult to maintain sales
One year after landing on the New York Stock Exchange, Kenvue, originally a consumer health business company for Johnson&Johnson, pressed the layoff button. On May 7th US time, Kenvue released its Q1 ... -
Johnson&Johnson will pay $6.5 billion to resolve a talcum powder cancer lawsuit
Johnson&Johnson announced on May 1st a restructuring plan proposed by its subsidiary LLT Management LLC (LLT) to comprehensively and ultimately resolve all current and future claims related to ovaria ... -
Johnson&Johnson will pay $6.5 billion to resolve a talcum powder cancer lawsuit
Johnson&Johnson announced on May 1st a restructuring plan proposed by its subsidiary LLT Management LLC (LLT) to comprehensively and ultimately resolve all claims related to ovarian cancer in current ... -
Johnson&Johnson announces acquisition of Shockwave with a total transaction value of approximately $13.1 billion
On April 5th, Johnson&Johnson and Shockwave Medical announced a final agreement to acquire all outstanding shares of Shockwave in cash at a price of $335 per share. The total value of this transactio ... -
Johnson&Johnson's sales reached $85.2 billion in 2023, a year-on-year increase of 6.5%
On January 23rd, Johnson&Johnson (NYSE: JNJ) released its fourth quarter and full year results for 2023. In the fourth quarter of 2023, the company reported sales of 21.4 billion US dollars, a year-o ... -
Can baby powder cause cancer? Johnson&Johnson is willing to spend 5 billion yuan to settle, but still faces over 50000 lawsuits
On January 8th, Bloomberg reported that insiders revealed that Johnson&Johnson (J&J) had initially agreed to pay approximately $700 million (approximately RMB 5 billion) to resolve an investigation i ... -
5 billion! Johnson&Johnson reportedly reached a settlement agreement on the investigation into the carcinogenicity of baby powder, but still faces over 50000 related lawsuits
On January 8th, Bloomberg reported, citing sources familiar with the matter, that Johnson&Johnson (NYSE: JNJ) has tentatively agreed to pay approximately $700 million (approximately RMB 5 billion) to ... -
Johnson&Johnson claims to have resolved some of the talc powder claims
Erik Haas, the global vice president in charge of litigation at Johnson&Johnson, stated during an investor conference call on December 5th local time that the company has recently reached a settlemen ... -
Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
Johnson&Johnson CEO Joaquin Duato stated at the company's Investor Day event on December 5th that the company currently has no plans to produce weight loss pills due to the intense competition in the ...